目的：评价南京地区医院分子靶向抗肿瘤药的利用情况。方法：采用销售金额和用药频度（DDDs）分析及排序法，对南京地区33家医院2010-2012年分子靶向抗肿瘤药的利用情况进行分析。结果：该地区医院分子靶向抗肿瘤药的销售金额和DDDs逐年增加，年均增长率分别为35.39％和18.56％。3年总销售金额排名靠前的是利妥昔单抗、重组人血管内皮抑制素、曲妥珠单抗和吉非替尼，而3年总DDDs排名靠前的是吉非替尼、重组人血管内皮抑制素和厄洛替尼。各年度销售金额排前3位的制药企业均为罗氏制药有限公司、山东先声麦得津生物制药有限公司和阿斯利康贸易有限公司。结论：2010-2012年南京地区分子靶向抗肿瘤药应用呈上升趋势，分子靶向药物越来越得到临床认可。%OBJECTIVE:To evaluate the clinical utilization of molecular targeted anti-tumor drugs in Nanjing city. METH-ODS:The utilization of molecular targeted anti-tumor drugs in 33 hospitals of Nanjing city during 2010-2012 period was analyzed statistically with regard to consumption sum and DDDs. RESULTS:The consumption sum and DDDs of molecular targeted drugs in Nanjing city increased year by year,with annual growth rate of 35.39% and 18.56%,respectively. From 2010 to 2012,the top four drugs in consumption sum were rituximab,recombinant human endostatin,trastuzumab and gefitinib;the top three drugs in DDDs were gefitinib,recombinant human endostatin and erlotinib;the top three manufacturers ranked by sales amount were Roche Pharmaceuticals Co. Ltd.,Shandong Simcere-Medgenn Bio-pharmaceutical Co. Ltd. and Astrazeneca Trading Co. Ltd. CONCLU-SIONS:The consumption of molecular targeted anti-tumor drugs in Nanjing city shows an upward trend from 2010 to 2012,indi-cating the increasing popularity of molecular targeted drugs.
展开▼
